These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 31471582)

  • 41. Polymorphic variants in the p53 pathway.
    Murphy ME
    Cell Death Differ; 2006 Jun; 13(6):916-20. PubMed ID: 16557270
    [No Abstract]   [Full Text] [Related]  

  • 42. Tumor suppressor p53 and its gain-of-function mutants in cancer.
    Liu J; Zhang C; Feng Z
    Acta Biochim Biophys Sin (Shanghai); 2014 Mar; 46(3):170-9. PubMed ID: 24374774
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Regulation of the p53 tumor suppressor protein.
    Oren M
    J Biol Chem; 1999 Dec; 274(51):36031-4. PubMed ID: 10593882
    [No Abstract]   [Full Text] [Related]  

  • 44. Reactivating mutant p53 using small molecules as zinc metallochaperones: awakening a sleeping giant in cancer.
    Blanden AR; Yu X; Loh SN; Levine AJ; Carpizo DR
    Drug Discov Today; 2015 Nov; 20(11):1391-7. PubMed ID: 26205328
    [TBL] [Abstract][Full Text] [Related]  

  • 45. MicroRNAs in the p53 network: micromanagement of tumour suppression.
    Hermeking H
    Nat Rev Cancer; 2012 Sep; 12(9):613-26. PubMed ID: 22898542
    [TBL] [Abstract][Full Text] [Related]  

  • 46. What is the potential of p53 isoforms as a predictive biomarker in the treatment of cancer?
    Hayman L; Chaudhry WR; Revin VV; Zhelev N; Bourdon JC
    Expert Rev Mol Diagn; 2019 Feb; 19(2):149-159. PubMed ID: 30582376
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [miR-34s--a tumor suppression protein p53 highly related microRNA].
    Lou WJ; Chen Q; Liu L; Qian C
    Yi Chuan; 2010 May; 32(5):423-30. PubMed ID: 20466628
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical implications of the p53 tumor-suppressor gene.
    Harris CC; Hollstein M
    N Engl J Med; 1993 Oct; 329(18):1318-27. PubMed ID: 8413413
    [No Abstract]   [Full Text] [Related]  

  • 49. Mutant p53 exerts oncogenic effects through microRNAs and their target gene networks.
    Li XL; Jones MF; Subramanian M; Lal A
    FEBS Lett; 2014 Aug; 588(16):2610-5. PubMed ID: 24726728
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Role of the lncRNA-p53 regulatory network in cancer.
    Zhang A; Xu M; Mo YY
    J Mol Cell Biol; 2014 Jun; 6(3):181-91. PubMed ID: 24721780
    [TBL] [Abstract][Full Text] [Related]  

  • 51. P53 and prognosis: new insights and further complexity.
    Vousden KH; Prives C
    Cell; 2005 Jan; 120(1):7-10. PubMed ID: 15652475
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [The p53 gene and protein in 2005: new results, promising opportunities].
    Szoke D; Sipos F; Spisák S; Molnár B; Tulassay Z
    Orv Hetil; 2005 Jul; 146(30):1587-94. PubMed ID: 16136736
    [TBL] [Abstract][Full Text] [Related]  

  • 53. p53 Antibodies in the sera of patients with various types of cancer: a review.
    Soussi T
    Cancer Res; 2000 Apr; 60(7):1777-88. PubMed ID: 10766157
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Tumor suppressor gene p53. Theoretical principles and their significance for pathology].
    Poremba C; Bankfalvi A; Dockhorn-Dworniczak B
    Pathologe; 1996 May; 17(3):181-8. PubMed ID: 8710788
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Living with p53, dying of p53.
    Aylon Y; Oren M
    Cell; 2007 Aug; 130(4):597-600. PubMed ID: 17719538
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mutant TP53 posttranslational modifications: challenges and opportunities.
    Nguyen TA; Menendez D; Resnick MA; Anderson CW
    Hum Mutat; 2014 Jun; 35(6):738-55. PubMed ID: 24395704
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The tumor suppressor protein p53: a receptor to genotoxic stress that controls cell growth and survival.
    Hainaut P
    Curr Opin Oncol; 1995 Jan; 7(1):76-82. PubMed ID: 7696367
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The expanding universe of p53 targets.
    Menendez D; Inga A; Resnick MA
    Nat Rev Cancer; 2009 Oct; 9(10):724-37. PubMed ID: 19776742
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Nothing to gain for p53.
    Harjes U
    Nat Rev Cancer; 2019 Oct; 19(10):544-545. PubMed ID: 31471582
    [No Abstract]   [Full Text] [Related]  

  • 60. [Advances on mutant p53 research].
    Li DH; Zhang LQ; He FC
    Yi Chuan; 2008 Jun; 30(6):697-703. PubMed ID: 18550490
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.